The potential for using protein vaccines to protect against otitis media caused by Streptococcus pneumoniae.
about
Pneumococcal conjugate vaccines for preventing vaccine-type invasive pneumococcal disease and pneumonia with consolidation on x-ray in children under two years of ageMouse models for human otitis mediaFrom in vitro to in vivo Models of Bacterial Biofilm-Related Infections.Intranasal vaccination with pneumococcal surface protein A and interleukin-12 augments antibody-mediated opsonization and protective immunity against Streptococcus pneumoniae infection.Streptococcus pneumoniae Otitis Media Pathogenesis and How It Informs Our Understanding of Vaccine Strategies.MyD88 signaling is not essential for induction of antigen-specific B cell responses but is indispensable for protection against Streptococcus pneumoniae infection following oral vaccination with attenuated Salmonella expressing PspA antigen.Mapping of epitopes recognized by antibodies induced by immunization of mice with PspA and PspC.Immunization with recombinant Streptococcus pneumoniae neuraminidase NanA protects chinchillas against nasopharyngeal colonization.Immune responses to recombinant pneumococcal PspA antigen delivered by live attenuated Salmonella enterica serovar typhimurium vaccineAge-specific immunoglobulin g (IgG) and IgA to pneumococcal protein antigens in a population in coastal kenya.Search for potential vaccine candidate open reading frames in the Bacillus anthracis virulence plasmid pXO1: in silico and in vitro screening.Identification of invasive serotype 1 pneumococcal isolates that express nonhemolytic pneumolysin.PspA family distribution, antimicrobial resistance and serotype of Streptococcus pneumoniae isolated from upper respiratory tract infections in JapanRegions of PspA/EF3296 best able to elicit protection against Streptococcus pneumoniae in a murine infection modelNatural antibodies against several pneumococcal virulence proteins in children during the pre-pneumococcal-vaccine era: the generation R study.Current state of pneumococcal vaccines.Designed reduction of Streptococcus pneumoniae pathogenicity via synthetic changes in virulence factor codon-pair biasEvaluation of a vaccine formulation against Streptococcus pneumoniae based on choline-binding proteins.Animals devoid of pulmonary system as infection models in the study of lung bacterial pathogensRelative roles of genetic background and variation in PspA in the ability of antibodies to PspA to protect against capsular type 3 and 4 strains of Streptococcus pneumoniaeAn evaluation of emerging vaccines for childhood pneumococcal pneumonia.Genetic relationship between Streptococcus pneumoniae isolates from nasopharyngeal and cerebrospinal fluid of two infants with Pneumococcal Meningitis.Antibody-independent, CD4+ T-cell-dependent protection against pneumococcal colonization elicited by intranasal immunization with purified pneumococcal proteins.Fusion proteins containing family 1 and family 2 PspA fragments elicit protection against Streptococcus pneumoniae that correlates with antibody-mediated enhancement of complement deposition.Pneumococcal surface protein A inhibits complement deposition on the pneumococcal surface by competing with the binding of C-reactive protein to cell-surface phosphocholineStreptococcus pneumoniae protein vaccine candidates: properties, activities and animal studies.Mouse models as a tool to unravel the genetic basis for human otitis media.The love-hate relationship between bacterial polysaccharides and the host immune system.Analysis of type II secretion of recombinant pneumococcal PspA and PspC in a Salmonella enterica serovar Typhimurium vaccine with regulated delayed antigen synthesis.Nanogel-based PspA intranasal vaccine prevents invasive disease and nasal colonization by Streptococcus pneumoniae.Distribution of pneumococcal surface protein A families 1 and 2 among Streptococcus pneumoniae isolates from children in finland who had acute otitis media or were nasopharyngeal carriers.Novel Strategy To Protect against Influenza Virus-Induced Pneumococcal Disease without Interfering with Commensal ColonizationCharacterization of protective mucosal and systemic immune responses elicited by pneumococcal surface protein PspA and PspC nasal vaccines against a respiratory pneumococcal challenge in mice.PspA family fusion proteins delivered by attenuated Salmonella enterica serovar Typhimurium extend and enhance protection against Streptococcus pneumoniaeLarge-scale identification of serotype 4 Streptococcus pneumoniae virulence factorsA modified surface killing assay (MSKA) as a functional in vitro assay for identifying protective antibodies against pneumococcal surface protein A (PspA).Current status and perspectives on protein-based pneumococcal vaccines.Viability and virulence of pneumolysin, pneumococcal surface protein A, and pneumolysin/pneumococcal surface protein A mutants in the ear.Pneumolysin plays a key role at the initial step of establishing pneumococcal nasal colonization.Immunogenicity and protective immunity against otitis media caused by pneumococcus in mice of Hib conjugate vaccine with PsaA protein carrier.
P2860
Q24245934-1B4914F3-B2AE-4E77-ACF2-447230F93A76Q27491017-9CE17AEA-2AC9-40F9-8261-B91F39F7C96AQ30424697-E2635BCC-C047-4854-92B9-4C18E4035C14Q33552360-5572556E-4ADC-4E88-B13F-04DD4F3F1FCCQ33733347-1327037F-FCB8-4A8C-804E-A96DC2FF10CCQ33776975-3FD49A76-A867-4A23-97D6-4893F4AB5644Q33899358-9BEBE225-C05B-4459-94E1-F7034BB89B16Q34111722-E0F3DD47-9C26-4E79-808E-9CBEE974324AQ34120949-74321951-8000-4A30-ABF4-894252628257Q34145758-9BD08A85-09D3-42B3-A5AF-8FDC481E4F59Q34262140-8C762D4B-A192-49BE-BC78-E3540131374BQ34315525-3D27EDCE-F2FE-49A3-96F1-754C57C089F5Q34618641-CEC955FF-9BCC-42F7-B799-7D6E03605316Q34713678-80D1695F-A353-4B2F-BBAF-2A6211350F13Q34740228-20A1FAEC-CC6B-4CD7-BB63-97459613D4BFQ34744239-042C9613-C694-4959-B2D9-1B09D91176A9Q34754860-EADD7641-4FA0-48F9-BD71-ADDCEDD09108Q35021099-ECC192CD-E84A-4544-8D5B-6F77AFD9D6E3Q35048029-4F0A1CA0-030A-4C7F-95A4-2FA9F087BF1EQ35165275-6F213685-E6EC-41FB-A585-485248492229Q35595931-76BBBA98-DFC2-44FD-B463-8832C112F88FQ35636628-1D8B37AE-48B6-4C4C-A1BC-81B6F422E2BFQ36313904-E0026276-55E1-4532-BFDD-353677C9CBE2Q36314000-BACBCA68-30B6-40A0-9FB2-4B4B55867188Q36454995-F58EC649-F217-4CFA-8D56-4F23204F4A02Q36558990-E399D1B3-467E-475A-97E6-903A3284E01DQ36569492-78D51873-BD82-4566-B452-7FEF24BE0450Q36615936-C1B4B72A-A0D7-4182-8783-0B7823801699Q36747183-944588A6-AB79-46F1-8EA5-987C42D8F630Q36826926-54D4AF44-260B-402B-8B9C-6523704E2343Q36933015-84965828-9D7F-4040-B109-3BFBD1A91A49Q37002290-B755334E-E068-4E3B-A2AE-6A54F8DE67C7Q37190966-31E06931-9DA2-4F31-90E0-7962450DFBC7Q37355855-56C1A1B7-C2E9-4B91-972E-3ADD61A27463Q37459576-5E47E15F-774F-409E-800C-D5AF7166F0E0Q37483596-9907505D-1D2E-467D-92C9-0389773AC25EQ38124921-BF7584D0-8399-4D6D-8078-3C74BCF43F7DQ40039505-77EF051F-BF41-482F-8C3D-F8FF2A0CF4D1Q40068619-8055C7D1-C572-4B3A-AEBA-153E641F414DQ40533459-51B9987D-3B84-417F-B882-219897253574
P2860
The potential for using protein vaccines to protect against otitis media caused by Streptococcus pneumoniae.
description
2000 nî lūn-bûn
@nan
2000 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
name
The potential for using protei ...... d by Streptococcus pneumoniae.
@ast
The potential for using protei ...... d by Streptococcus pneumoniae.
@en
The potential for using protei ...... d by Streptococcus pneumoniae.
@nl
type
label
The potential for using protei ...... d by Streptococcus pneumoniae.
@ast
The potential for using protei ...... d by Streptococcus pneumoniae.
@en
The potential for using protei ...... d by Streptococcus pneumoniae.
@nl
prefLabel
The potential for using protei ...... d by Streptococcus pneumoniae.
@ast
The potential for using protei ...... d by Streptococcus pneumoniae.
@en
The potential for using protei ...... d by Streptococcus pneumoniae.
@nl
P2093
P1433
P1476
The potential for using protei ...... d by Streptococcus pneumoniae.
@en
P2093
Brooks-Walter A
Hollingshead SK
P304
P356
10.1016/S0264-410X(00)00285-1
P407
P478
19 Suppl 1
P577
2000-12-01T00:00:00Z